What changed for Primary Biliary Cholangitis

How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.

Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.

• Trials recruiting worldwide 55 to 53 (-2)
• Late-stage (Phase 3) trials 11 to 12 (+1)
• Trials on record 276 to 271 (-5)

Newly subsidised on the PBS

No medicines were newly subsidised on the PBS for Primary Biliary Cholangitis in July 2026. Voxsanity tracks 3 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.

Past updates

Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.

Recent trend

Recent trial results

The 30 most recent of 57 trials tracked for Primary Biliary Cholangitis that have reported results to a public registry.

AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

• NCT05239468 · results posted 16 July 2026

  According to the results reported on ClinicalTrials.gov, this trial enrolled 72 participants across four groups, all of whom had a liver condition being monitored through blood markers. Each group received a different combination of two medicines — obeticholic acid (OCA) or a placebo (inactive treatment), paired with either a lower or higher dose of bezafibrate (BZF). The main thing the trial was measuring was the change in a liver enzyme called alkaline phosphatase (ALP) — a substance in the blood that doctors use to monitor certain liver conditions — over a 12-week double-blind period (where...

  View reported results on ClinicalTrials.gov ↗

• NCT04594694 · results posted 16 July 2026

  According to the results reported on ClinicalTrials.gov, this trial (NCT04594694) enrolled 75 adults across four treatment groups during its main double-blind phase (lasting up to three years). The four groups each received a different combination of two medicines: obeticholic acid (OCA) or a placebo, paired with one of two forms of bezafibrate (a lower-dose immediate-release version at 200 mg, or a higher-dose slow-release version at 400 mg). The trial was primarily measuring changes in a liver enzyme called alkaline phosphatase (ALP) — a substance in the blood that doctors use as a marker wh...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT06488911 · results posted 8 June 2026

  According to the results reported on ClinicalTrials.gov, this trial enrolled 62 participants, all of whom received a combination of two medicines: obeticholic acid (OCA) at 5 mg and bezafibrate (BZF) at 400 mg. The trial was measuring safety-related information — specifically, how many participants experienced unwanted medical events (called adverse events) while taking the combination, including any serious events or events that caused someone to stop taking the medicines. It is noted that none of the 62 participants were recorded as having "completed" the study, with all 62 listed under "not...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗

• NCT05642468 · results posted 4 May 2026

  According to the results reported on ClinicalTrials.gov, this trial tested three different doses of an investigational drug called A3907 in a small number of participants: 8 people received 10 mg once daily, 6 received 30 mg once daily, and 4 received 30 mg twice daily (the twice-daily group also used something called a controlled-release system, or CRS). In total, 18 people started the trial, but only 10 completed it — 2, 3, and 3 people respectively did not finish in each group. The trial was primarily measuring how many participants experienced medical events (called adverse events) that ar...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗

• NCT03710122 · results posted 22 April 2026

  According to the results reported on ClinicalTrials.gov, this trial (NCT03710122) enrolled 82 adults with a liver condition called primary sclerosing cholangitis (PSC) — 40 received oral vancomycin (an antibiotic taken by mouth) and 42 received a placebo (a dummy treatment). The trial ran for up to 24 months and was primarily measuring levels of a liver enzyme called alkaline phosphatase (ALP) in the blood — a marker that doctors monitor in people with this condition. Fewer participants remained in the trial over time: by the end of the 18-month treatment period, 15 in the vancomycin group and...

  View reported results on ClinicalTrials.gov ↗

• NCT04480840 · results posted 23 January 2026

  According to the results reported on ClinicalTrials.gov, this trial tested an investigational drug called PLN-74809 across four different dose levels, compared against a placebo (a dummy treatment with no active ingredient). A total of 121 people took part — 30 in the placebo group and 91 across the four dose groups. The trial's main focus was on tracking unwanted medical events (called adverse events) that occurred or got worse after participants started taking the study drug or placebo. A secondary focus was measuring how much of the drug was present in participants' blood at certain time po...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT05525520 · results posted 31 July 2025

  According to the results reported on ClinicalTrials.gov, this trial enrolled 62 people in total. For the first six weeks, 30 participants received a placebo (an inactive dummy tablet) followed by the study drug EP547, while 32 received EP547 throughout. The trial was mainly measuring changes in itch severity using a scoring tool called the Worst Itch Numeric Rating Scale (WI-NRS), where 0 means no itching and 10 means the worst itching imaginable. Several other itch-related questionnaires were also tracked as secondary measurements. The reported data shows that, over the first six weeks, the...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗

• NCT04950127 · results posted 22 July 2025

  According to the results reported on ClinicalTrials.gov, this trial tested a medicine called linerixibat (40 mg) against a placebo (an inactive dummy treatment) in people with a condition that causes itching. The trial ran in two parts: Part A lasted 24 weeks, and Part B ran from week 24 to week 32. In Part A, 119 people were assigned to linerixibat and 119 to placebo. Participants rated their itching and sleep disruption on a scale of 0 to 10 (where 0 means none and 10 means the worst imaginable), and these scores were tracked over time. The reported data shows that, on average over the 24 w...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT02704364 · results posted 17 June 2025

  According to the results reported on ClinicalTrials.gov, this trial looked at a drug called NGM282 in people with a liver condition called Primary Sclerosing Cholangitis (PSC), which causes scarring of the bile ducts. A total of 62 people took part — 21 received a lower dose of NGM282 (1.0 mg), 21 received a higher dose (3.0 mg), and 20 received a placebo (a dummy treatment with no active ingredient). The trial mainly measured changes in a liver enzyme in the blood called alkaline phosphatase, which doctors often monitor in people with PSC. It also tracked several other liver-related substance...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT05014672 · results posted 24 April 2025

  According to the results reported on ClinicalTrials.gov, this trial (NCT05014672) enrolled 76 people in total — 24 in the setanaxib 1,200 mg/day group, 25 in the setanaxib 1,600 mg/day group, and 27 in the placebo group. The trial was measuring the effects of two different daily doses of a drug called setanaxib compared to a dummy (placebo) treatment in people with a liver condition called primary biliary cholangitis (PBC). The main thing being measured was a change in a liver enzyme called ALP (alkaline phosphatase) after 24 weeks. Several secondary measurements looked at fatigue and liver st...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗

• NCT02609048 · results posted 25 February 2025

  According to the results reported on ClinicalTrials.gov, this trial enrolled 41 people across three groups: 13 received seladelpar 200 mg, 14 received seladelpar 50 mg, and 14 received a placebo (an inactive dummy treatment). The trial was primarily measuring changes in a liver enzyme called alkaline phosphatase (AP) — a substance in the blood that doctors sometimes monitor in liver conditions. Only a small number of participants completed the full study: 2 in the 200 mg group, 4 in the 50 mg group, and 4 in the placebo group, meaning most participants did not finish. The reported data shows...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT05292872 · results posted 24 January 2025

  According to the results reported on ClinicalTrials.gov, this study looked at 4,577 people with a liver condition called primary biliary cholangitis (PBC). Of these, 403 were treated with a medicine called obeticholic acid (OCA), and 4,174 were treated with other approaches that did not include OCA. The study was observational — meaning it looked at real-world health records rather than randomly assigning people to treatments — and it tracked whether participants experienced serious liver-related events over time, including death from any cause, liver transplant, or hospital admission for cert...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT04024813 · results posted 16 January 2025

  According to the results reported on ClinicalTrials.gov, this trial (NCT04024813) enrolled only one participant, who was assigned to receive a placebo (an inactive treatment used as a comparison). The trial was designed to study a condition called Primary Sclerosing Cholangitis (PSC), a disease affecting the liver's bile ducts. The main thing the trial set out to measure was a change in a liver-related blood marker (called alkaline phosphatase) after 24 weeks, along with several other measures such as disease-related symptoms, liver disease progression, and any unwanted health events experienc...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗

• NCT03112681 · results posted 19 September 2024

  According to the results reported on ClinicalTrials.gov, this trial looked at a medicine called saroglitazar magnesium in people with a liver condition called primary biliary cholangitis. A total of 37 people took part — 14 received the 2 mg dose, 13 received the 4 mg dose, and 10 received a placebo (a dummy treatment with no active ingredient). The trial ran for 16 weeks. By the end, 13, 10, and 9 people in each of those three groups respectively had completed the study. The main thing the trial was measuring was the change in a substance in the blood called alkaline phosphatase (ALP) — a ma...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT04526665 · results posted 5 September 2024

  According to the results reported on ClinicalTrials.gov, this trial (NCT04526665) enrolled 161 people with primary biliary cholangitis (PBC), a liver condition. Of these, 108 were assigned to take elafibranor 80 mg daily and 53 received a placebo (a dummy tablet with no active ingredient). The trial ran for 52 weeks. It was measuring changes in certain liver-related blood markers — mainly a substance called alkaline phosphatase (ALP) and total bilirubin — to see how many participants reached pre-set target levels by the end of the year. Around 94 people in the elafibranor group and 46 in the p...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT03545672 · results posted 9 August 2024

  According to the results reported on ClinicalTrials.gov, this trial enrolled 60 people with a liver condition called primary biliary cholangitis (PBC) and 59 people without the condition who acted as a comparison (control) group. The trial was looking at whether people with PBC showed any differences in heart-related measurements compared to healthy controls. A small number of participants did not finish the study — four in the PBC group and three in the control group — leaving 56 completers in each group. The reported data shows two main things were measured. First, the trial tracked whether...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT04620733 · results posted 25 July 2024

  According to the results reported on ClinicalTrials.gov, this trial (NCT04620733) looked at a medicine called seladelpar compared to a placebo (a dummy treatment with no active ingredient) in 193 people in total — 65 received the placebo and 128 received seladelpar. The trial was measuring two main things: whether certain liver-related blood markers reached target levels after 12 months, and what unwanted events or changes in blood tests were recorded during the study. It also looked at changes in itching scores as a secondary measure. The reported data shows that for the main blood marker go...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT04604652 · results posted 24 April 2024

  According to the results reported on ClinicalTrials.gov, this trial (NCT04604652) enrolled 24 adult participants, all of whom completed the study — none dropped out. All participants had a liver condition called primary biliary cholangitis (PBC) and had not responded well enough to their standard treatment. Every participant received the same investigational medicine, HTD1801, at a dose of 1,000 mg twice daily for 12 weeks. The trial was measuring changes in several blood markers — substances that doctors use to monitor liver and immune system activity — comparing levels at the start of the st...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗

• NCT03890120 · results posted 29 November 2023

  According to the results reported on ClinicalTrials.gov, this trial (NCT03890120) looked at a drug called cilofexor (100 mg) compared to a placebo (a dummy tablet with no active ingredient) in people with liver disease. A total of 419 people took part in the main blinded phase — 278 received cilofexor and 141 received placebo — over roughly two years (about 100 weeks). Neither the participants nor the researchers knew who was getting which treatment during this phase. A smaller follow-on open-label extension phase (where everyone knew they were receiving cilofexor) then ran for about 45 weeks,...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT04060147 · results posted 27 July 2023

  According to the results reported on ClinicalTrials.gov, this trial enrolled 11 participants who all received the study drug cilofexor. Ten of the 11 participants completed the trial, and one did not finish. The trial was measuring how often participants experienced unwanted medical events (called adverse events) while taking the drug, including both general side effects and more serious ones, as well as any notable changes in their laboratory test results. The reported data shows that 81.8% of participants (roughly 9 out of 11) experienced at least one treatment-emergent adverse event — mean...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT02308111 · results posted 9 March 2023

  According to the results reported on ClinicalTrials.gov, this trial (NCT02308111) enrolled 168 people who received obeticholic acid (OCA) and 166 people who received a placebo (a dummy treatment), all of whom also received standard local care for primary biliary cholangitis (PBC), a chronic liver condition. The trial was measuring how long it took for serious liver-related events to occur — such as death, needing a liver transplant, or the liver becoming severely damaged — comparing the two groups over time. The reported data shows that none of the participants were recorded as having "complet...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT03394781 · results posted 17 October 2022

  According to the results reported on ClinicalTrials.gov, this trial enrolled a total of five people — three in a group receiving a 10 mg dose of a study drug called DUR-928, and two in a group receiving a 50 mg dose. All five participants completed the trial; none dropped out. The trial was measuring changes in certain liver-related substances in the blood — mainly a liver enzyme called alkaline phosphatase (ALP), along with other liver enzymes and bile acids (natural substances made by the liver) — to see how those levels shifted from the start of the trial to the end of treatment and a follo...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗

• NCT03633227 · results posted 6 September 2022

  According to the results reported on ClinicalTrials.gov, this trial (NCT03633227) enrolled 22 children and young people in total — 12 in the placebo group and 10 in the obeticholic acid (OCA) group — during the first phase of the study, which ran up to 48 weeks. The trial was primarily measuring how the body absorbed and processed OCA, a medicine being investigated for a liver condition. Specifically, researchers tracked how much of the drug reached the bloodstream, how quickly it peaked, and how long it stayed in the body. Relatively few participants completed the full double-blind phase (4 i...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT03602560 · results posted 31 May 2022

  According to the results reported on ClinicalTrials.gov, this trial (NCT03602560) looked at a medicine called seladelpar in people with a liver condition. A total of 265 people took part — 89 in a group that started on a lower dose of seladelpar (5 mg) and could move up to a higher dose (10 mg), 89 in a fixed higher-dose group (10 mg), and 87 in a placebo group (a dummy treatment with no active medicine). The trial was measuring whether seladelpar could hit a combination target related to a liver enzyme called alkaline phosphatase (ALP) and another liver marker called total bilirubin, checked...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗

• NCT03333928 · results posted 6 April 2022

  According to the results reported on ClinicalTrials.gov, this trial tested an investigational medicine called HTD1801 in people with a liver condition. Participants were split into three groups: one taking a lower dose of HTD1801 (500 mg twice daily), one taking a higher dose (1,000 mg twice daily), and one taking a placebo (a dummy treatment with no active ingredient). The trial ran in three back-to-back periods. In the first period, 16, 25, and 18 people started in each group respectively. The trial was primarily measuring changes in a liver enzyme in the blood called alkaline phosphatase (A...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT03155932 · results posted 24 March 2022

  According to the results reported on ClinicalTrials.gov, this trial (NCT03155932) enrolled 2 participants who were given a study drug called APD334 (also known as etrasimod). The trial was designed to look at two main things: changes in a blood marker called alkaline phosphatase (ALP) — a substance that, when elevated, can suggest a liver condition is progressing — and the number of participants who experienced any unwanted or unexpected health events (called adverse events) during the study. Both participants started the trial, both moved on to a higher dose at the 12-week mark, and both comp...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗

• NCT03359174 · results posted 9 August 2021

  According to the results reported on ClinicalTrials.gov, this trial looked at a treatment called All-trans Retinoic Acid (ATRA) in people with a liver condition. The trial set out to measure changes in certain blood markers — including a liver enzyme called alkaline phosphatase (ALP), bile acids, and other indicators of liver health — by comparing blood test results before and after treatment. Only 2 people enrolled in the trial, 1 of whom completed it and 1 of whom did not finish. The reported data shows that no numerical results were submitted to ClinicalTrials.gov for any of the outcome me...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗

• NCT03722576 · results posted 2 June 2021

  According to the results reported on ClinicalTrials.gov, this trial (NCT03722576) enrolled 18 people, all of whom received a treatment called vidofludimus calcium. Eleven participants completed the study, while seven did not finish. The trial was looking at changes in certain liver-related blood markers — specifically alkaline phosphatase (ALP, an enzyme linked to liver and bone activity) and aspartate aminotransferase (AST, an enzyme linked to liver and muscle cells) — to see how levels of these substances changed over 24 weeks. The reported data shows that for the main (primary) outcome, 3...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗

• NCT03394924 · results posted 18 May 2021

  According to the results reported on ClinicalTrials.gov, this trial tested two doses of an investigational drug called EDP-305 (1 mg and 2.5 mg) against a placebo (an inactive treatment) in 68 people in total — 31 in the 1 mg group, 28 in the 2.5 mg group, and 9 in the placebo group. The trial ran for 12 weeks and was primarily measuring whether participants' blood levels of a liver enzyme called alkaline phosphatase (ALP) — a marker sometimes monitored in liver conditions — dropped by at least 20%, or returned to a normal range, by the end of the study. The reported data shows that 45.2% of...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗

• NCT02966834 · results posted 4 May 2021

  According to the results reported on ClinicalTrials.gov, this trial enrolled 147 people in total across six groups. Participants had primary biliary cholangitis (PBC), a liver condition, and were experiencing itching. The trial was measuring whether different doses of a medicine called GSK2330672 — taken either once or twice a day — changed the severity of itching compared to a dummy treatment (placebo) over roughly 16 weeks. The study also looked at certain liver-related markers in the blood, and at participants' quality of life using a standardised questionnaire. The reported data shows tha...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

See all 57 reported results for Primary Biliary Cholangitis

These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.

What is coming

AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

According to NIH funding data, a moderate amount of public research funding is currently directed toward Primary Biliary Cholangitis, and encouragingly, that level of investment has been rising over time. This upward trend suggests that researchers and funding bodies are increasingly recognising the condition as a priority worth pursuing. For patients, a growing public research base generally mean...

See the full Primary Biliary Cholangitis page

Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.